[BLOOD COAGULATION AND FIBRINOLYSIS DURING ORAL AND PARENTERAL MEDICATION OF N,N'-DIMETHYL-N,N'-BIS-(3-(3',4',5'-TRIMETHOXYBENZOXY)-PROPYL)-ETHYLENEDIAMINE DIHYDROCHLORIDE IN HUMANS WITH NORMAL BLOOD COAGULATION AND ON SUSTAINED ANTICOAGULANT THERAPY].
D000925:Anticoagulants; D035843:Biomedical Research; D001777:Blood Coagulation; D004358:Drug Therapy; D005029:Ethylenediamines; D005342:Fibrinolysis; D006801:Humans; D010600:Pharmacology; D014665:Vasodilator Agents
D000925:Anticoagulants; D005029:Ethylenediamines; D014665:Vasodilator Agents; C031234:ethylenediamine
ANTICOAGULANTS; BLOOD COAGULATION; CLINICAL RESEARCH; DRUG THERAPY; ETHYLENEDIAMINES; FIBRINOLYSIS; PHARMACOLOGY; VASODILATOR AGENTS
BLUTGERINNUNG UND FIBRINOLYSE DES MENSCHEN WAEHREND ORALER UND PARENTERALER MEDIKATION VON N,N'-DIMETHYL-N,N'-BIS-